(MENAFN- PR Newswire) SEOUL, South Korea, Jan. 25, 2023 /PRNewswire/ -- GenKOre, Inc., a Korea-based biotech company with hypercompact
CRISPR-Cas tools,
announced that it has
entered into
a
strategic research collaboration with a US-based
biopharma
company for the development of
in vivo
gene
editing
therapies. This
collaboration will utilize
GenKOre's
proprietary
CRISPR-Cas
platform,
TaRGET
(Tiny nuclease,
augment
RNA-based
Genome
Editing
Technology). The
TaRGET
platform is distinct from the most popular
genome editing technology,
CRISPR-Cas9,
in that the whole editing module can be delivered with a single AAV vector. Based on
their
TaRGET platform,
GenKOre
has developed different
modalities
of editing tools including
TaRGET-CUT,
TaRGET-Adenine Base Editing (ABE),
TaRGET-AI (Gene Activation and Inhibition system).
and
TaRGET-FREE
(Gene knock-in)
.
continue reading
'This collaboration reflects the strength and
potential
utility of
TaRGET
platform in the application of
in vivo
gene-editing therapy', said Yong-Sam Kim, CEO
of
GenKOre. 'Not only will this collaboration provide an opportunity to validate the applicability of
TaRGET
platform to
in vivo
therapy, but we will also expand the utility of our technologies to a wider spectrum of rare diseases.' The collaboration
was
built on the mutual
interest
in
forging transformative therapeutics for patients with rare diseases.
Under the terms of the agreement,
GenKOre
will receive
up to
300 million USD including an upfront, option exercise fees and milestone payments upon successful achievement of
R&D
and commercial milestones across two
in vivo
disease targets. In addition,
GenKOre
will receive research funding and tiered royalties up to a double-digit percentage of net sales.
SOURCE GenKOre
MENAFN25012023003732001241ID1105478082
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.